Abstract:
:Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A phase III trial is under way to compare its safety and efficacy with that of standard chemotherapy.
journal_name
Cancer Discovjournal_title
Cancer discoveryauthors
doi
10.1158/2159-8290.CD-NB2019-034subject
Has Abstractpub_date
2019-05-01 00:00:00pages
570issue
5eissn
2159-8274issn
2159-8290pii
2159-8290.CD-NB2019-034journal_volume
9pub_type
评论,新闻相关文献
Cancer Discovery文献大全abstract::In a first-in-human trial of an anti-CD22 chimeric antigen receptor T-cell therapy in children and young adults with relapsed and refractory acute lymphocytic leukemia, researchers found that the immunotherapeutic approach was not only feasible and safe, but also effective, leading to remissions in most patients. Infu...
journal_title:Cancer discovery
pub_type:
doi:10.1158/2159-8290.CD-NB2017-001
更新日期:2017-02-01 00:00:00
abstract::Investigators have discovered that a certain type of immune cell in tumors, known as tissue-resident memory cells, are associated with a strong immune response and improved prognosis in lung cancer. The findings may aid in selecting appropriate immunotherapies and developing more effective vaccines for a wide range of...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2017-104
更新日期:2017-09-01 00:00:00
abstract::Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms. Inhibition of MEK1/2 by trametinib in patients ...
journal_title:Cancer discovery
pub_type: 临床试验,杂志文章
doi:10.1158/2159-8290.CD-16-0653
更新日期:2017-03-01 00:00:00
abstract::Accelerated review and greater understanding of tumor biology speed targeted treatments to patients. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-ND11-09
更新日期:2011-10-01 00:00:00
abstract::Unconventional T-lymphocyte populations are emerging as important regulators of tumor immunity. Despite this, the role of TCRαβ+CD4-CD8-NK1.1- innate αβ T cells (iαβT) in pancreatic ductal adenocarcinoma (PDA) has not been explored. We found that iαβTs represent ∼10% of T lymphocytes infiltrating PDA in mice and human...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-19-0161
更新日期:2019-09-01 00:00:00
abstract:UNLABELLED:Colorectal cancer was one of the first solid tumors to be classified on the basis of molecular profiling. Microsatellite instability has allowed researchers to distinguish a specific subtype of colorectal cancer that has a clearly identified molecular origin (mismatch repair deficiency), arises on a heredita...
journal_title:Cancer discovery
pub_type: 杂志文章,评审
doi:10.1158/2159-8290.CD-12-0471
更新日期:2013-05-01 00:00:00
abstract::T cell-based therapies have induced cancer remissions, though most tumors ultimately progress, reflecting inherent or acquired resistance including antigen escape. Better understanding of how T cells eliminate tumors will help decipher resistance mechanisms. We used a CRISPR/Cas9 screen and identified a necessary role...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-20-0756
更新日期:2020-12-17 00:00:00
abstract::Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia telangiectasia mutated (ATM) signaling. We report the dose-escalation portion of the phase I first-in-h...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-20-0868
更新日期:2020-09-28 00:00:00
abstract::A new study of all 32 cancer types in The Cancer Genome Atlas identifies genomic alterations that increase the activity of the PI3K/AKT/mTOR pathway. The study, which combines mutation data with measures of protein levels and phosphorylation status, suggests that mutations in IDH1, VHL, and STK11 promote activation of...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2017-092
更新日期:2017-08-01 00:00:00
abstract::Sen and colleagues have shown for the first time the clinical application of an oligonucleotide decoy targeting the oncogenic transcription factor STAT3 for the treatment of head and neck tumors. Intratumoral injection of decoy effectively reduced the activity of STAT3 as evidenced by a decrease in several of its tran...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-12-0310
更新日期:2012-08-01 00:00:00
abstract:UNLABELLED:Genetic approaches have shown that the p110β isoform of class Ia phosphatidylinositol-3-kinase (PI3K) is essential for the growth of PTEN-null tumors. Thus, it is desirable to develop p110β-specific inhibitors for cancer therapy. Using a panel of PI3K isoform-specific cellular assays, we screened a collectio...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-12-0003
更新日期:2012-05-01 00:00:00
abstract::Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2017-123
更新日期:2017-10-01 00:00:00
abstract::According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-NB2019-066
更新日期:2019-08-01 00:00:00
abstract::A new report from the World Health Organization and the NCI estimates that the worldwide cost of smoking-due to health problems and lost productivity-exceeds $1 trillion annually, with the biggest economic burden falling on low- and middle- income countries. That's because proven interventions, such as tax and price i...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2017-014
更新日期:2017-03-01 00:00:00
abstract::The FDA authorized 23andMe to market the first direct-to-consumer test to check for three BRCA1/2 mutations associated with a higher risk of developing breast, ovarian, and prostate cancers. The mutations are most commonly found in about 2% of women of Ashkenazi Jewish descent. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2018-031
更新日期:2018-05-01 00:00:00
abstract::Primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) drugs are clinically relevant problems in patients with metastatic colorectal carcinoma. A complex network of molecular alterations is involved in this phenomenon. Bertotti et al. report the development of serially transplantable groups of...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-11-0261
更新日期:2011-11-01 00:00:00
abstract::Oncogenes induce premature S phase, resulting in replication-transcription conflicts and replication stress. ...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-RW2018-039
更新日期:2018-04-01 00:00:00
abstract::Whether metastases were seeded mono- or polyclonally depended on cancer site and treatment. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-RW2020-082
更新日期:2020-07-01 00:00:00
abstract::HDAC inhibitors synergize with PI3K inhibitors to reduce MYC-driven medulloblastoma (MB) growth. ...
journal_title:Cancer discovery
pub_type: 评论,信件
doi:10.1158/2159-8290.CD-RW2016-052
更新日期:2016-05-01 00:00:00
abstract::Preliminary findings from a recent study suggest that combining intermittent fasting or a fasting-mimicking diet with endocrine therapy for hormone receptor-positive breast cancer may improve treatment efficacy and reduce side effects. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-NB2020-084
更新日期:2020-11-01 00:00:00
abstract::Activation of AKT signaling by PTEN loss or PIK3CA mutations occurs frequently in human cancers, but targeting AKT has been difficult due to the mechanism-based toxicities of inhibitors that target the inactive conformation of AKT. Ipatasertib (GDC-0068) is a novel selective ATP-competitive small-molecule inhibitor of...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-16-0512
更新日期:2017-01-01 00:00:00
abstract::The PD-1 inhibitor pembrolizumab in combination with chemotherapy may be an effective therapy for patients with newly diagnosed advanced non-squamous non-small cell lung cancer. In a clinical trial, patients who received the combination had an estimated 12-month overall survival rate of 69.2%, compared with 49.4% in p...
journal_title:Cancer discovery
pub_type: 评论,新闻
doi:10.1158/2159-8290.CD-NB2018-051
更新日期:2018-06-01 00:00:00
abstract:UNLABELLED:RNA interference (RNAi) is a potent and specific mechanism for regulating gene expression. Harnessing RNAi to silence genes involved in disease holds promise for the development of a new class of therapeutics. Delivery is key to realizing the potential of RNAi, and lipid nanoparticles (LNP) have proved effec...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-12-0429
更新日期:2013-04-01 00:00:00
abstract::Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alt...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-18-0275
更新日期:2018-09-01 00:00:00
abstract::Treating human breast cancer xenografts in mice with bevacizumab or sunitinib has increased the population of cancer stem cells found in the tumors. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2012-013
更新日期:2012-03-01 00:00:00
abstract::Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-19-0532
更新日期:2020-07-01 00:00:00
abstract::The pks+E. coli metabolite colibactin caused a unique mutational signature in intestinal organoids. ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-RW2020-037
更新日期:2020-05-01 00:00:00
abstract:UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...
journal_title:Cancer discovery
pub_type: 杂志文章
doi:10.1158/2159-8290.CD-13-0830
更新日期:2014-10-01 00:00:00
abstract::Even in diffuse large B-cell lymphoma (DLBCL), a cancer of professional antigen-presenting cells, response rates to immune checkpoint blockade therapy have been limited. One reason for DLBCL immune evasion is epigenetic repression instead of activation of the antigen-presenting MHC-a dissection of mechanisms underlyin...
journal_title:Cancer discovery
pub_type: 评论,杂志文章
doi:10.1158/2159-8290.CD-19-0090
更新日期:2019-04-01 00:00:00
abstract::A report from the Presidential Commission for the Study of Bioethical Issues offers several recommendations to help protect the privacy of patients who have whole-genome sequencing. ...
journal_title:Cancer discovery
pub_type: 新闻
doi:10.1158/2159-8290.CD-NB2012-124
更新日期:2012-12-01 00:00:00